HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 286/6/F1144    most recent 00236.2003v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (7) Citing Articles via Google Scholar Google Scholar Articles by Lasaitiene, D. Articles by Chen, Y. Search for Related Content PubMed PubMed Citation Articles by Lasaitiene, D. Articles by Chen, Y.

Neonatal RAS inhibition changes the phenotype of the developing thick ascending limb of Henle

¹Department of Physiology, Institute of Physiology and Pharmacology, and ²Department of Clinical Physiology, University of Gothenburg, 413 90 Gothenburg; and ³Department of Pathology and Cytology, Karolinska Hospital, 171 76 Stockholm, Sweden

Submitted 30 June 2003 ; accepted in final form 4 February 2004

Pharmacological interruption of angiotensin II type 1 (AT₁) receptor signaling during nephrogenesis in rats perturbs renal tubular development. Perturbed tubulogenesis may contribute to long-term impairment of urinary concentrating ability, which is the main functional irreversible defect. The aim of this study was to further characterize tubular developmental deficits in neonatal rats, focusing on the thick ascending limb of Henle (TALH), known to undergo profound developmental changes and to be involved in urine-concentrating mechanisms. We have carried out immunohistochemistry and Western immunoblotting using antibodies directed against the major histocompatibility complex class II (MHC II) molecule and different TALH-specific markers, namely, cyclooxygenase-2 (COX-2), Tamm-Horsfall glycoprotein (THP), and the bumetanide-sensitive Na⁺-K⁺-2Cl^– cotransporter (BSC-1/NKCC2). Immunohistochemistry demonstrated expression of MHC II, COX-2, THP, and BSC-1/NKCC2 proteins in normally developing TALH cells. The AT₁-receptor antagonist losartan abolished MHC II expression exclusively in the developing TALH cells. Increased expression of COX-2 and THP was observed in the TALH cells of losartan-treated rats. Western immunoblotting confirmed increases in cortical and medullary COX-2 and THP abundance and revealed a decrease in cortical BSC-1/NKCC2 abundance in response to losartan treatment. We conclude that neonatal losartan treatment causes significant changes in the phenotype of the developing TALH in the rat.

renal development; AT₁ receptor blockade; major histocompatibility complex class II molecule; cyclooxygenase-2; Tamm-Horsfall glycoprotein; bumetanide-sensitive sodium-potassium-chloride cotransporter

This article has been cited by other articles:

				F. G. Machado, E. P. B. Poppi, C. Fanelli, D. M. A. C. Malheiros, R. Zatz, and C. K. Fujihara AT1 blockade during lactation as a model of chronic nephropathy: mechanisms of renal injury Am J Physiol Renal Physiol, June 1, 2008; 294(6): F1345 - F1353. [Abstract] [Full Text] [PDF]

				C. M. Coleman, J. J. Minor, L. E. Burt, B. A. Thornhill, M. S. Forbes, and R. L. Chevalier Angiotensin AT1-receptor inhibition exacerbates renal injury resulting from partial unilateral ureteral obstruction in the neonatal rat Am J Physiol Renal Physiol, July 1, 2007; 293(1): F262 - F268. [Abstract] [Full Text] [PDF]